Pulmatrix Inc
NASDAQ:PULM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pulmatrix Inc
Deferred Income Tax
Pulmatrix Inc
Deferred Income Tax Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Deferred Income Tax | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pulmatrix Inc
NASDAQ:PULM
|
Deferred Income Tax
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Deferred Income Tax
$6.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
1%
|
CAGR 10-Years
9%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Deferred Income Tax
$222m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Deferred Income Tax
$2.4B
|
CAGR 3-Years
33%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-21%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Deferred Income Tax
$1.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-14%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Deferred Income Tax
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pulmatrix Inc
Glance View
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The company is headquartered in Lexington, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2014-03-21. The company designs and develops inhaled therapeutic products based on its dry powder delivery technology, inhaled small particles easily respirable and emitted (iSPERSE), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. iSPERSE’s lead development program, Pulmazole is its inhaled formulation of itraconazole, an anti-fungal drug commercially available as an oral drug, which it is developing to treat and prevent pulmonary fungal infections. PUR1800 is developing for the treatment of acute exacerbations of chronic obstructive pulmonary disease and PUR3100 is developing for the treatment of acute migraine.
